Net Health, the leader in software solutions for specialized outpatient care, has developed functionality within its WoundExpert® software that will provide WoundExpert clients the opportunity to participate in Nuo Therapeutics’ Coverage with Evidence Development program (CED) with the Centers for Medicare and Medicaid Services for its Aurix platelet and plasma therapy system. Effective August 17, WoundExpert clients that choose to participate in the Aurix CED program will be able to identify patients that may qualify for participation in the CED, track the necessary data points for those enrolled patients, and produce the required documentation for Medicare reimbursement.
Aurix is a biodynamic hematogel introduced by Gaithersburg, Maryland-based Nuo Therapeutics (OTCQX:NUOT). According to Nuo Therapeutics, it is the first platelet and plasma therapy system to be cleared by the FDA for the management of ulcers and wounds of all types (diabetic foot ulcer, pressure ulcer, venous leg ulcer, etc.) and severities.
Net Health’s Chief Technology Officer, Christopher F. Hayes, explains the opportunity for their clients, “Once live, WoundExpert clients can elect to turn on functionality that activates necessary Aurix CED patient screening and data collection protocols and can automatically generate documentation required for the Medicare claims process.”
Study participation is designed to feel seamless to providers. While working within their typical patient visit flow, providers will be flagged if the patient is a pre-qualified candidate for CED participation and can easily report the data needed to determine a patient’s eligibility. If selected, the required data will be captured inside WoundExpert during typical wound care visits.
Hayes adds, “We’re pleased to be working with Nuo Therapeutics on this CED program because we believe in driving quality of care, and expanding care options, through data-based evidence. Given Net Health’s expertise with specialized outpatient care, we’re perfectly fitted to further efforts in this space.”
Nuo Therapeutics’ Chief Commercial Officer, Dean Tozer, states, “WoundExpert is the leading clinical documentation and EHR software solution in wound care. We’re thrilled to be collaborating with them to enable providers to better identify and track patients throughout the Aurix CED program.”
About Nuo Therapeutics
Nuo Therapeutics, Inc. (the “Company”) is a biomedical company that pioneers leading-edge biodynamic therapies for wound care. The Company’s flagship product, Aurix™ is a biodynamic hematogel that harnesses a patient’s innate regenerative abilities for the management of a variety of wounds. For additional information please visit www.nuot.com.